Recruiting

Observational Study

Sponsor:

St. Jude Children's Research Hospital

Code:

NCT06477289

Conditions

Sickle Cell Disease

Eligibility Criteria

Sex: All

Age: 12 - 25

Healthy Volunteers: Not accepted

Study Details

Brief summary:

This study will examine sleep disordered breathing and sleep quality in participants (ages 12-25) diagnosed with sickle cell disease of any genotype. We will utilize remote peripheral arterial tonometry (PAT) and questionnaires to evaluate difficulties with sleep. PAT assessments will occur remotely in the homes of participants.

Neurocognitive, behavioral, and neuroimaging evaluations will occur on the same day as a routine clinic visit.

Primary Objective:

Evaluate the relationship between nocturnal oxyhemoglobin saturation (SpO2) and neurocognitive functioning (working memory and verbal comprehension) in individuals (ages 12-25) diagnosed with sickle cell disease controlling for age, genotype, and social vulnerability.

Secondary Objective:

Assess differences in white matter integrity, silent cerebral infarcts, neuroinflammation, and functional connectivity among individuals (ages 12-25) diagnosed with sickle cell disease with and without sleep disordered breathing after controlling for age.

Assess differences in self- and caregiver-reported mood and pain severity among individuals (ages 12-25) diagnosed with sickle cell disease with and without sleep disordered breathing after controlling for age.

Exploratory Objectives:

Explore the relationship between nocturnal oxyhemoglobin saturation (SpO2) and neurocognitive functioning (attention, processing speed, verbal memory, visual memory, motor dexterity) in individuals (ages 12-25) diagnosed with sickle cell disease controlling for age, genotype, and social vulnerability.

Assess the feasibility of an optical imaging tool (Speckle Contrast Optical Spectroscopy - Open-Motion 3.0) to measure cerebral blood flow and blood volume in patients diagnosed with sickle cell disease (ages 12-25).

Assess the concordance between measurement of cerebral blood flow and volume using speckle contrast optical spectroscopy and arterial spin labeling brain MRI.

Conditions

Sickle Cell Disease

Study ID

NCT06477289

Start date

Sep 16, 2024

Status verified date

Jun, 2026

Completion date

Jun, 2028

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 12 - 25

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Diagnosed with sickle cell disease of any genotype
  • Participant in the Sickle Cell Clinical Research and Intervention Program
  • Between 12-25 years of age at the time of enrollment
  • English is the primary language
  • Access to an electronic device with WiFi

Exclusion Criteria:

  • History of an intellectual disability
  • History of a traumatic brain injury or seizure disorder
  • History of a stroke
  • Undergoing potential curative treatment for SCD (stem cell transplant or gene therapy)
  • Currently prescribed an intervention for a sleep disorder
  • Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.

Study Design

Enrollment

65 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Evaluate the relationship between nocturnal oxyhemoglobin saturation (SpO2) and neurocognitive functioning (working memory and verbal comprehension) in individuals (ages 12-25) diagnosed with sickle cell disease. [ Time Frame: Baseline remote sleep assessment over 3 days followed by in-clinic assessment. ]

Central Contacts and Locations

Central contacts

Locations

St. Jude Children's Research Hospital

Recruiting

Memphis, Tennessee, United States, 38105

Contacts

More Information

Sponsor

St. Jude Children's Research Hospital

Last update posted

Jun 29, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by St. Jude Children's Research Hospital on 2026-06-29.